|
13.08.2024 23:04:23
|
EQS-Adhoc: Marinomed Biotech AG applies for court restructuring proceedings without self-administration
|
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Insolvency/Restructure of Company Korneuburg, Austria, 13. August 2024 – Marinomed Biotech AG (VSE:MARI) announces to apply for the initiation of court restructuring proceedings. The aim is to carry out restructuring proceedings without self-administration.
As a result of the inability to raise funds required at short notice to secure the Company’s liquidity, insolvency is imminent. As announced, revenue expectations for the 2024 financial year could not yet be realized as planned. Aim of the restructuring proceedings without self-administration is to sustainably secure the Company’s financial stability according to a restructuring plan. For this purpose, besides restructuring measures, proceeds including from the realization of strategic options regarding the Carragelose business are intended to be used. The publication of the half-year financial statements planned for August 20, 2024, has been postponed. +++ End of ad-hoc announcement +++ End of Inside Information
13-Aug-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 1967439 |
| End of Announcement | EQS News Service |
|
|
1967439 13-Aug-2024 CET/CEST
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Marinomed Biotech AGmehr Nachrichten
|
19.11.24 |
Verluste in Wien: ATX Prime am Nachmittag im Minus (finanzen.at) | |
|
18.11.24 |
Börse Wien in Grün: ATX Prime steigt schlussendlich (finanzen.at) | |
|
18.11.24 |
Gewinne in Wien: ATX Prime am Montagnachmittag stärker (finanzen.at) | |
|
18.11.24 |
Gewinne in Wien: ATX Prime liegt mittags im Plus (finanzen.at) | |
|
15.11.24 |
Freitagshandel in Wien: ATX Prime schließt in der Gewinnzone (finanzen.at) | |
|
15.11.24 |
ATX Prime-Handel aktuell: ATX Prime fällt zum Handelsstart (finanzen.at) | |
|
14.11.24 |
Gute Stimmung in Wien: ATX Prime bewegt letztendlich im Plus (finanzen.at) | |
|
14.11.24 |
Börse Wien: So performt der ATX Prime nachmittags (finanzen.at) |
Analysen zu Marinomed Biotech AGmehr Analysen
| 19.09.23 | Marinomed Biotech kaufen | Erste Group Bank | |
| 05.04.23 | Marinomed Biotech kaufen | Erste Group Bank | |
| 20.09.22 | Marinomed Biotech kaufen | Erste Group Bank | |
| 05.04.22 | Marinomed Biotech kaufen | Erste Group Bank | |
| 14.09.21 | Marinomed Biotech kaufen | Erste Group Bank |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.